A comparison of intravenous immunoglobulin (2g/kg totally) and single doses of anti-D immunoglobulin at 50μg/kg, 75μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience

We conducted this prospective randomized trial of intravenous immunoglobulin (IVIG) treatment in children with newly diagnosed immune thrombocytopenic purpura (ITP) to compare the efficacy of IVIG to standard and higher doses of anti-D IVIG. Seventy-eight patients who were previously untreated and between the age of 1 and 18 years with newly diagnosed acute ITP and a platelet concentration less than 20×10/l were eligible for enrollment. In this study IVIG treatment was compared with two different doses of anti-D. Study patients were randomized to receive treatment according to one of the two single anti-D IVIG doses [50μg/kg (n=19) or 75μg/kg (n=20)] or 2g/kg (400mg/kg per day, 5 day) total dose of IVIG (n=39). There is a significant increase of 24th hour, 48th hour, 72nd hour, 7th day and 30th day platelet counts in IVIG (2g/kg, total dose) group compared to anti-D IVIG 50μg/kg and anti-D IVIG 75μg/kg groups. However, there were no difference between 24th hour, 48th hour, 72nd hour, 7th day and 30th day platelet counts across anti-D IVIG 50μg/kg and anti-D IVIG 75μg/kg groups. In conclusion, this study suggests that IVIG is well tolerated and significantly more effective than standard and high-dose anti-D IVIG for the treatment of newly diagnosed ITP in children. Apart from this, we believe that IVIG might be the first-line treatment of these patients. Regarding this issue further prospective studies comparing different IVIG treatment regimens with anti-D IVIG treatment regimens are needed. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.